Macrocure's CureXcell Phase III Leg Ulcer Study Futile

Israeli stem cell company Macrocure's lead wound-healing product CureXcell has stumbled in a US Phase III study in venous leg ulcers (VLU) – with a futility analysis revealing that it is not expected to meet its primary endpoint. Shares in the firm dropped by 72% to £3.33 in early trading on Nasdaq on Aug. 20, from a previous day's close of $12.05.